| Bioactivity | AChE-IN-63 (Compound 5AD) is a selective inhibitor of hAChE (IC50=0.103 μM). AChE-IN-63 also inhibits hBChE and hBACE-1 (IC50= 10 μM (hBChE); 1.342 μM (hBACE-1)). AChE-IN-63 inhibits Aβ aggregation, preventing the formation and deposition of Aβ1-42. AChE-IN-63 can effectively penetrate the blood-brain barrier and is orally effective. It is primarily used in Alzheimer's disease research[1]. |
| Invitro | AChE-IN-63 (5-20 μM; 48 h) 以浓度依赖性的抑制 Aβ1-42 的聚集[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> AChE-IN-63 相关抗体: |
| In Vivo | AChE-IN-63 (p.o.; 100 mg/kg; 单剂量) 在瑞士白化小鼠中没有表现出任何毒性或异常反应[1]。AChE-IN-63 (p.o.; 5-20 mg/kg; 单剂量) 在东莨菪碱 (HY-N0296) Y 迷宫模型中改善了认知功能障碍小鼠的学习和记忆能力，展现了良好的抗氧化性性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 876685-78-8 |
| Formula | C18H19N5O |
| Molar Mass | 321.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Singh A, et al. Structure-Guided Design, Synthesis, and Biological Evaluation of Peripheral Anionic Site Selective and Brain Permeable Novel Oxadiazole-Piperazine Conjugates against Alzheimer's Disease with Antioxidant Potential. ACS Omega. 2024 Apr 11;9(16):18169-18182. |